Vitrectomy with intraocular cyclophotocoagulation for the treatment of neovascular glaucoma

Objective To evaluate the efficacy of vitrectomy combined with intraocular cyclophotocoagulation for the treatment of neovascular glaucoma (NVG) secondary to proliferative diabetic retinopathy (PDR). Methods The data of 52 eyes of 52 patients with NVG secondary to PDR in this hospital from Sep. 2017 to Apr. 2018 were analyzed retrospectively. All patients underwent intravitreal ranibizumab injection. Vitrectomy and panretinal photocoagulation were performed at 7 days after injection. There were 26 cases in clinical trial group and 26 cases in control group. Vitrectomy and intraocular cyclophotocoagulation were performed in the trial group. Cyclophotocoagulation was performed with 20 G laser fiber during the operation. The control group accepted vitrectomy alone. Results There was no significant difference in baseline data between the two groups (P>0.05). At 6 months postoperatively, the obvious iris new blood vessels were subsided in 17 eyes (65.4%) of the trial group and 15 eyes (57.7%) of the control group, respectively (P=0.569). There was no significant difference in BCVA between the two groups at 1 week, 3 months and 6 months after operation (P=0.596, 0.587, 0.671), and the intraocular pressure in the trial group was lower than that in the control group(P=0.003, 0.000, 0.000). Conclusion Intravitreal injection of ranibizumb combined with vitrectomy and intraocular cyclophotocoagulation for NVG secondary to PDR can promote neovascular regression and effectively reduce intraocular pressure. Key words: Retinopathy, diabetic, proliferative; Glaucoma, neovascular; Vitrectomy; Ranibizumab, intravitreal injection; Cyclophotocoagulation